Willsher P C, Beaver J, Blamey R W, Robertson J F
Professorial Department of Surgery, City Hospital, Nottingham, U.K.
Anticancer Res. 1995 Jul-Aug;15(4):1609-11.
Pre-treatment TPS serum levels from patients with Stage IV breast cancer (n = 66) (1386.0 +/- 3504.5) were significantly higher (p < 0.0001), than normal controls (n = 47), (75.5 +/- 111.5 U/L), benign breast disease patients (n = 84) (58.5 +/ 57.1 U/L), and breast cancer patients with Stage I/II (n = 79) (52.7 +I- 49.5U/L) or Stage III disease (n = 57) (166.7 +/- 218.8). Analysis of sequentially obtained samples from Stage IV patients during endocrine treatment showed TPS alone or in combination with CEA and CA 15.3 was less accurate in predicting response than the combination of CEA with CA 15.3. In this study TPS did not usefully add to the established marker combination of CEA and CA 15.3.
IV期乳腺癌患者（n = 66）的治疗前TPS血清水平（1386.0 +/- 3504.5）显著高于正常对照组（n = 47）（75.5 +/- 111.5 U/L）、良性乳腺疾病患者（n = 84）（58.5 +/ 57.1 U/L）以及I/II期乳腺癌患者（n = 79）（52.7 +I- 49.5U/L）或III期疾病患者（n = 57）（166.7 +/- 218.8）（p < 0.0001）。对IV期患者在内分泌治疗期间连续获取的样本进行分析显示，单独使用TPS或与CEA和CA 15.3联合使用在预测反应方面不如CEA与CA 15.3联合使用准确。在本研究中，TPS对已确立的CEA和CA 15.3标志物组合并无有效补充作用。
